{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:29:24Z","timestamp":1781620164374,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a neurodegenerative disease that results in progressive and symmetric muscle weakness and atrophy of the proximal limbs and trunk due to degeneration of spinal alpha-motor neurons. Children are classified into types 1\u20133, from severe to mild, according to the time of onset and motor ability. Children with type 1 are the most severe, are unable to sit independently, and experience a series of respiratory problems, such as hypoventilation, reduced cough, and sputum congestion. Respiratory failure is easily complicated by respiratory infections and is a major cause of death in children with SMA. Most type 1 children die within 2 years of age. Type 1 children with SMA usually require hospitalization for lower respiratory tract infections and invasive ventilator-assisted ventilation in severe cases. These children are frequently infected with drug-resistant bacteria due to repeated hospitalizations and require long hospital stays requiring invasive ventilation. In this paper, we report a case of nebulization combined with intravenous polymyxin B in a child with spinal muscular atrophy with extensively drug-resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> pneumonia, hoping to provide a reference for the treatment of children with extensively drug-resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> pneumonia.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1163341","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:45:05Z","timestamp":1687340705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: A case of spinal muscular atrophy with extensively drug-resistant Acinetobacter baumannii pneumonia treated with nebulization combined with intravenous polymyxin B: experience and a literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Bingqing","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-016-0127-7","article-title":"Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia:a pro- spective,randomised trial","volume":"6","author":"Abdellatif","year":"2016","journal-title":"Ann. Intensive Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3760\/cma.j.issn.0376-2491.2012.02.002","article-title":"Expert consensus on the diagnosis, treatment and prevention and control of acinetobacter baumannii infection in China","volume":"2","author":"Chen","year":"2012","journal-title":"Natl. Med. J. China"},{"key":"B3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3870\/j.issn.1004-0781.2019.02.001","article-title":"The Expert Consensus on the Rational Use of Nebulization Therapy (2019 Edition)","volume":"38","year":"2019","journal-title":"Herald Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3760\/cma.j.issn.1671-0282.2019.10.007","article-title":"Chinese expert consensus on the clinical application of polymyxin [J]","volume":"28","year":"2019","journal-title":"Chin. J. Emerg. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-016-0123-7","article-title":"Is inhaled colistin benefi- cial in ventilator associated pneumonia or nosocomial pneumonia caused by acinetobacter baumannii","volume":"15","author":"Demirdal","year":"2016","journal-title":"Ann. Clin. Micro Biol. Antimicrobials"},{"key":"B6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/0883073811420152","article-title":"The natural history of infant spinal muscular atrophy in China: a study of 237 patients","volume":"27","author":"Ge","year":"2012","journal-title":"J. Child Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3760\/cma.j.cn101070-20190715-00637","article-title":"Clinical characteristics of 13 children with spinal muscular atrophy combined with pneumonia","volume":"35","author":"Guo","year":"2020","journal-title":"Chin. J. Appl. Clin. Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3969\/j.issn.1008-1070.2016.11.004","article-title":"Diagnosis and treatment of respiratory diseases related to spinal muscular atrophy","volume":"51","author":"Guo","year":"2016","journal-title":"Chin. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2478\/jccm-2020-0044","article-title":"The susceptibility of MDR-k. pneumoniae to polymyxin b plus its nebulised form versus polymyxin b alone in critically ill south Asian patients","volume":"7","author":"Hasan","year":"2021","journal-title":"J. Crit. Care Med. (Targu Mures)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3969\/j.issn.1673-5501.2021.06.002","article-title":"Antimicrobial resistance profile of clinical strains isolated from children in China: a report from the ISPED program of 2020","volume":"16","author":"He","year":"2021","journal-title":"Chin. J. Evidence Based Pediatr."},{"key":"B11","unstructured":"CHINET surveillance of antimicrobial resistance among the bacterial isolates in 2021\n            HuF.\n            GuoY.\n            ZhuD.\n            WangF.\n            JiangX.\n            XuY.\n          10.16718\/j.1009-7708.2022.05.001Chin J Infect Chemother222021"},{"key":"B12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3760\/cma.j.cn112147-20201109-01091","article-title":"Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China","volume":"44","year":"2021","journal-title":"Chin. J. Tubercul. Respir. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3760\/cma.j.cn112147-20200531-00656","article-title":"Topical application of antimicrobial agents for lower airway infection in adults: a Chinese expert consensus","volume":"44","year":"2021","journal-title":"Chin. J. Tubercul. Respir. Dis."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.902054","article-title":"Effectiveness and nephrotoxicity of intravenous polymyxin b in carbapenem-resistant gram-negative bacterial infections among Chinese children","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/1060028016649598","article-title":"Physicochemical stability study of polymyxin b in various infusion solutions for administra- tion to critically ill patients","volume":"50","author":"Lim","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.13507\/j.issn.1674-3474.2021.11.025","article-title":"Polymyxin b for postoperative carbapenem-resistant gram-negative bacteria-infected pneumonia in children with congenital heart disease","volume":"35","author":"Liu","year":"2021","journal-title":"J. Chin. Pract. Diagnosis Ther."},{"key":"B18","first-page":"39","article-title":"acute respiratory failure secondary to polymyxin b inhalation","volume":"3","author":"Ma","year":"1982","journal-title":"J. Hebei Med. Coll."},{"key":"B19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.diagmicrobio.2007.01.008","article-title":"Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant gram-negative bacilli with inhaled polymyxin b","volume":"58","author":"Pereira","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"876","DOI":"10.7501\/j.issn.1674-5515.2022.04.037","article-title":"Clinical analysis of polymyxins b in treatment of hospital acquired pneumonia with carbapenem-resistant gram-negative bacteria in children","volume":"37","author":"Wu","year":"2022","journal-title":"Drugs Clinic"},{"key":"B24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3760\/cma.j.cn121430-20201215-00753","article-title":"Clinical study on intravenous combined with aerosol inhalation of polymyxin b for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria","volume":"33","author":"Zhou","year":"2021","journal-title":"China Crit. Care Med."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1163341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:45:21Z","timestamp":1687340721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1163341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":24,"alternative-id":["10.3389\/fcimb.2023.1163341"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1163341","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"article-number":"1163341"}}